Jules Bordet

Type: Person
Name: Jules Bordet
First reported 8 hours ago - Updated 8 hours ago - 1 reports

NeoALTTO Trial: For HER2-Positive Breast Cancer, pCR Leads to Increased Overall Survival

Image ToolsWomen diagnosed with breast cancer who are able to achieve a pathological complete response (pCR) to treatment with HER2-receptor antagonists appear to have significantly longer overall and event-free survival, according to a study reported ... [Published Oncology Times - 8 hours ago]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Primary zonal high intensity focused ultrasound for prostate cancer: Results of a prospective phase IIa feasibility study - Abstract

Aims: In this study we report our results with storage of cryopreserved semen intended for preservation and subsequent infertility treatment in men with testicular cancer during the last 18 years.Methods: Cryopreserved semen of 523 men with testicular ... [Published UroToday - Apr 01 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight

IntroductionChange is coming to the NSCLC treatment algorithm—and it’s coming soon. Revolutionary new immunotherapies, more personalised treatment choices and further drug developments are all set to roll out in the near future. What are the potential ... [Published MarketResearch.com - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Afinitor/Aromasin combo disappoints in breast cancer trial

A combination of Novartis' Afinitor and Pfizer's Aromasin failed to reach statistical significance in a trial’s secondary endpoint of overall survival.Eagerly-awaited results from the BOLERO-2 trial looking at the mTOR inhibitor Afinitor (everolimus) ... [Published Pharma Times - Mar 25 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

Volpara Solutions Launches Two Quantitative Breast Imaging Tools to...

Showcasing VolparaAnalytics and VolparaDose at ECR for the First Time Volpara Solutions today announced the launch of VolparaAnalytics and VolparaDose, two new quantitative breast imaging software tools built on the Volpara algorithm which enables the ... [Published PRWeb - Mar 07 2014]
First reported Jan 14 2014 - Updated Jan 14 2014 - 1 reports

arGEN-X begins phase Ib expansion cohorts with ARGX-110 in cancer patients

arGEN-X, a clinical stage human therapeutic antibody company, has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its phase Ib study. The objective is to further investigate the safety of ARGX-110 in CD70-positive ... [Published PharmaBiz - Jan 14 2014]
Entities: ArGEN-X BV, Tumor, Flemish
First reported Nov 19 2013 - Updated Nov 19 2013 - 1 reports

Kiadis enrols patients in phase II clinical trial with ATIR for treatment of blood cancer

Kiadis Pharma BV, a clinical stage biopharmaceutical company developing treatments for blood cancers, has successfully enrolled approximately 10 patients, in phase II clinical trial, of whom the majority have already been transplanted and received ATIR. ... [Published PharmaBiz - Nov 19 2013]

More Content

All (9) | News (9) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
NeoALTTO Trial: For HER2-Positive Breast Cancer... [Published Oncology Times - 8 hours ago]
Primary zonal high intensity focused ultrasound... [Published UroToday - Apr 01 2014]
Non-small cell lung cancer: Game changing immun... [Published MarketResearch.com - Mar 26 2014]
Afinitor/Aromasin combo disappoints in breast c... [Published Pharma Times - Mar 25 2014]
Hormone Refractory Breast Cancer Global Clinica... [Published BioPortfolio - Mar 21 2014]
Volpara Solutions Launches Two Quantitative Bre... [Published PRWeb - Mar 07 2014]
arGEN-X begins phase Ib expansion cohorts with ... [Published PharmaBiz - Jan 14 2014]
Kiadis enrols patients in phase II clinical tri... [Published PharmaBiz - Nov 19 2013]
Spend link to cancer survival [Published Calcutta Telegraph - Sep 29 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.